564 related articles for article (PubMed ID: 6232320)
21. Immune adherence and staphylococcus protein A binding of soluble immune complexes produced by complement activation.
Schifferli JA; Peters DK
Clin Exp Immunol; 1983 Dec; 54(3):827-33. PubMed ID: 6228359
[TBL] [Abstract][Full Text] [Related]
22. Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes.
Gorgani NN; Parish CR; Easterbrook Smith SB; Altin JG
Biochemistry; 1997 Jun; 36(22):6653-62. PubMed ID: 9184145
[TBL] [Abstract][Full Text] [Related]
23. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
Vik DP; Fearon DT
J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
[TBL] [Abstract][Full Text] [Related]
24. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
25. Reduced complement-mediated immune complex solubilization in leprosy patients.
Ramanathan VD; Sharma P; Ramu G; Sengupta U
Clin Exp Immunol; 1985 Jun; 60(3):553-8. PubMed ID: 3874729
[TBL] [Abstract][Full Text] [Related]
26. Control of immune complexes by the classical pathway.
Whaley K; Ahmed AE
Behring Inst Mitt; 1989 Jul; (84):111-20. PubMed ID: 2529842
[TBL] [Abstract][Full Text] [Related]
27. Human F(ab')2-containing immune complexes together with anti-hinge natural antibodies stimulate complement amplification in vitro and in vivo.
Fumia S; Goede JS; Fischler M; Luginbühl A; Frick S; Fodor P; Lutz HU
Mol Immunol; 2008 May; 45(10):2951-61. PubMed ID: 18339427
[TBL] [Abstract][Full Text] [Related]
28. A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4.
Joiner KA; Goldman R; Schmetz M; Berger M; Hammer CH; Frank MM; Leive L
J Immunol; 1984 Jan; 132(1):369-75. PubMed ID: 6197449
[TBL] [Abstract][Full Text] [Related]
29. Prevention of immune precipitation by purified components of the alternative pathway.
Naama JK; Holme E; Hamilton E; Whaley K
Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
[TBL] [Abstract][Full Text] [Related]
30. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
Schifferli JA; Steiger G; Paccaud JP
Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
[TBL] [Abstract][Full Text] [Related]
31. Resistance to phagocytosis by group A streptococci: failure of deposited complement opsonins to interact with cellular receptors.
Weis JJ; Law SK; Levine RP; Cleary PP
J Immunol; 1985 Jan; 134(1):500-5. PubMed ID: 3880574
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
33. Competition for immune complexes by red cells in human blood.
Medof ME; Oger JJ
J Clin Lab Immunol; 1982 Jan; 7(1):7-13. PubMed ID: 7069779
[TBL] [Abstract][Full Text] [Related]
34. Characterization of C1q by monoclonal antibodies.
Heinz HP; Loos M
Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397
[TBL] [Abstract][Full Text] [Related]
35. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes.
Baatrup G; Svehag SE; Jensenius JC
Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458
[TBL] [Abstract][Full Text] [Related]
36. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
[TBL] [Abstract][Full Text] [Related]
37. The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.
Mann J; O'Brien R; Hostetter MK; Alper CA; Rosen FS; Babior BM
J Immunol; 1981 Jun; 126(6):2370-2. PubMed ID: 6785350
[TBL] [Abstract][Full Text] [Related]
38. The complement-mediated binding of soluble antibody/dsDNA immune complexes to human neutrophils.
Taylor RP; Burge J; Horgan C; Shasby DM
J Immunol; 1983 Jun; 130(6):2656-62. PubMed ID: 6854016
[TBL] [Abstract][Full Text] [Related]
39. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
[TBL] [Abstract][Full Text] [Related]
40. C3 binds preferentially to long-chain lipopolysaccharide during alternative pathway activation by Salmonella montevideo.
Joiner KA; Grossman N; Schmetz M; Leive L
J Immunol; 1986 Jan; 136(2):710-5. PubMed ID: 2416822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
